Intra-Cellular Therapies (ITCI) KOL Believes Caplyta Approval Could Create an Inflection - Jefferies
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $70.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI) after speaking to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
